Single Synapse Mass Spec Snags CD47 as Alzheimer’s Resilience Factor
Shooting synaptosomes through a mass spectrometer, scientists found that those with high CD47 and low ApoE were resilient in AD brain.
6066 RESULTS
Sort By:
Shooting synaptosomes through a mass spectrometer, scientists found that those with high CD47 and low ApoE were resilient in AD brain.
Scientists have turned their attention toward testing therapies in early-stage patients who have underlying brain pathology but little to no functional impairment...
The Journal of Neuroscience retracted a paper that claimed Aβ does not accumulate inside neurons, and temporarily banished its senior authors.
The United Kingdom’s exit from the European Union will likely slash funding, impede collaborations, and slow the pace of science.
Prior evidence for protective effect evaporates after adjustment for demographic differences in high- and low-lithium communities.
Aging lymphatic vessels in the meninges hinder waste clearance from the brain and exacerbate Aβ build-up.
First look at substrate interactions reveals similarities but some surprises.
The latest effort to determine if a non-steroidal anti-inflammatory drug protects against Alzheimer’s posted negative results. Time to abandon the approach?
In mice, the back of the brain, near the neck, contains lymphatic vessels that are specialized to take up cerebrospinal fluid and deliver it to cervical lymph nodes.
Researchers implicate PrP in the toxicity of Aβ, tau, and α-synuclein oligomers in several neurodegenerative diseases.
A survey of 16 purported conformation-specific antibodies found that most bound nearly equally well to oligomers and fibrils, and weakly to monomers.
A large multinational epidemiology study finds only small and inconsistent associations.
Instead of chewing up and disposing of the amyloid they ingest, microglia appear to compact it, then spit it back out as dense-core plaque.
Data from a Phase 2 trial also suggested that when amyloid dropped in treated brain, plasma p-tau217 followed suit. Using a CAMD progression model, Lilly claims the biomarker responses correlated with slower decline.
In a collaborative tour de force, scientists for the first time compared eight Aβ assays in the same plasma samples. Mass-spectrometry assays more accurately picked up brain amyloid than did most immunoassays, but one fully automated immunoassay was on par.
No filters selected